Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Lodrini

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2010
HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growthTill Milde, Ina Oehme, Andrey Korshunov, et al.
Cell Death & Disease|March 3, 2017
Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survivalTheresa M Thole, Marco Lodrini, Johannes Fabian, et al.
Journal of Neuro-Oncology|October 12, 2012
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatmentTill Milde, Marco Lodrini, Larissa Savelyeva, et al.
The Journal of Molecular Diagnostics : JMD|August 29, 2020
Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR ReactionConstantin Peitz, Annika Sprüssel, Rasmus B Linke, et al.
Acta Neuropathologica Communications|April 9, 2015
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastomaJonas Ecker, Ina Oehme, Ralph Mazitschek, et al.
Brain Pathology (Zurich, Switzerland)|May 10, 2012
Nestin expression identifies ependymoma patients with poor outcomeTill Milde, Thomas Hielscher, Hendrik Witt, et al.
Cancer Letters|February 25, 2026
Multiplexed biomarkers dynamically detect heterogeneous residual neuroblastoma cell clone activity in the bone marrow nicheAnna M Schroeer, Annika Winkler, Marion Fillies, et al.
International Journal of Cancer|December 7, 2020
Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastomaBirte Arlt, Christin Zasada, Katharina Baum, et al.
Nucleic Acids Research|April 30, 2013
MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastomaMarco Lodrini, Ina Oehme, Christina Schroeder, et al.
Journal of Clinical Medicine|October 26, 2024
Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses AngiogenesisAnnika Sprüssel, Takayoshi Suzuki, Naoki Miyata, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2010
HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growthTill Milde, Ina Oehme, Andrey Korshunov, et al.
Cell Death & Disease|March 3, 2017
Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survivalTheresa M Thole, Marco Lodrini, Johannes Fabian, et al.
Journal of Neuro-Oncology|October 12, 2012
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatmentTill Milde, Marco Lodrini, Larissa Savelyeva, et al.
The Journal of Molecular Diagnostics : JMD|August 29, 2020
Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR ReactionConstantin Peitz, Annika Sprüssel, Rasmus B Linke, et al.
Acta Neuropathologica Communications|April 9, 2015
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastomaJonas Ecker, Ina Oehme, Ralph Mazitschek, et al.
Brain Pathology (Zurich, Switzerland)|May 10, 2012
Nestin expression identifies ependymoma patients with poor outcomeTill Milde, Thomas Hielscher, Hendrik Witt, et al.
Cancer Letters|February 25, 2026
Multiplexed biomarkers dynamically detect heterogeneous residual neuroblastoma cell clone activity in the bone marrow nicheAnna M Schroeer, Annika Winkler, Marion Fillies, et al.
International Journal of Cancer|December 7, 2020
Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastomaBirte Arlt, Christin Zasada, Katharina Baum, et al.
Nucleic Acids Research|April 30, 2013
MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastomaMarco Lodrini, Ina Oehme, Christina Schroeder, et al.
Journal of Clinical Medicine|October 26, 2024
Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses AngiogenesisAnnika Sprüssel, Takayoshi Suzuki, Naoki Miyata, et al.
Pageof 4